Key result
Adding dipyridamole to aspirin in TIA or ischaemic stroke patients resulted in high on-treatment platelet reactivity in 71.4-86.8% of patients, with no significant change in CD62P/CD63 expression.
Why the study?
Data were limited on the ability of dipyridamole to additionally inhibit platelet function and reactivity in patients with ischaemic cerebrovascular disease receiving aspirin.
Does the addition of dipyridamole to aspirin improve platelet inhibition in TIA and ischaemic stroke patients?
Observational (n=60)
Does the addition of dipyridamole to aspirin improve platelet inhibition in TIA and ischaemic stroke patients?
A high proportion of TIA and ischemic stroke patients exhibit high on-treatment platelet reactivity when dipyridamole is added to aspirin, which is associated with increasing monocyte-platelet complexes.
Answers are grounded in this paper and cite their sources.
High on-treatment platelet reactivity persists with dipyridamole addition; leaves open its clinical relevance and requires outcome trials in TIA/stroke.
BACKGROUND: Data are limited on the ability of dipyridamole to additionally inhibit platelet function/reactivity in ischaemic cerebrovascular disease (CVD) patients on aspirin. AIMS: To assess inhibition of platelet function/reactivity and platelet activation with dipyridamole in CVD. METHODS: This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin. Platelet function/reactivity at high shear stress (PFA-100® C-ADP) and low shear stress (VerifyNow® P2Y12 and Multiplate® ADP assays), and platelet activation status (% expression of CD62P, CD63 and leucocyte-platelet complexes on whole blood flow cytometry) were quantified. 'Dipyridamole-high on-treatment platelet reactivity (HTPR)' was defined as failure to inhibit ADP-induced platelet aggregation +/- adhesion compared with the patient's baseline on aspirin monotherapy by more than twice the coefficient-of-variation of the assay after adding dipyridamole to aspirin. RESULTS: Dipyridamole-HTPR was identified in 71.4-75% of patients on PFA-100 C-ADP, 83.9-86.8% of patients on VerifyNow P2Y12, and 81.5-83.3% of patients on Multiplate ADP assays. There were no changes in CD62P/CD63 expression (P ≥ 0.18), or consistent changes in leucocyte-platelet complexes in CVD patients overall at 14d or 90d vs. baseline after commencing dipyridamole. Monocyte-platelet complexes increased in the patient subgroup with dipyridamole-HTPR at 14d and 90d on PFA-100, and at 14d on VerifyNow (P ≤ 0.04), but not in those without dipyridamole-HTPR. DISCUSSION: Additional antiplatelet effects of dipyridamole are detectable under high and low shear stress conditions with user-friendly platelet function/reactivity tests ex vivo. Increasing circulating monocyte-platelet complexes over time are associated with dipyridamole-HTPR.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2022) conducted an observational in TIA and ischaemic stroke (n=60). Addition of dipyridamole to aspirin vs. Baseline (aspirin monotherapy) was evaluated on Inhibition of platelet function/reactivity and platelet activation status (p=≥ 0.18). Adding dipyridamole to aspirin in TIA or ischaemic stroke patients resulted in high on-treatment platelet reactivity in 71.4-86.8% of patients, with no significant change in CD62P/CD63 expression.
Synapse has enriched 10 related papers. Consider them for comparative context: